CYTK Q2 2020 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-49.7% YoY

Gross Profit

-$18M-506.5% margin

Operating Income

-$32M-900.6% margin

Net Income

-$41M-1135.0% margin

EPS (Diluted)

$-0.68

QoQ Revenue Growth

-6.1%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$28M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$232M

Total Liabilities

$311M

Stockholders' Equity

-$78M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$7M	-49.7%
Gross Profit	-$18M	-$17M	-7.8%
Operating Income	-$32M	-$27M	-21.1%
Net Income	-$41M	-$32M	-27.0%

Revenue Segments

Research And Development

$4M63%

Research And Development Milestone Grant And Other Revenues Net

$2M37%